Table 3.
Summary of the ongoing studies on GBM immunotherapies testing CVs.
| Trial Name | Phase | Patients (N) | Treatment | Outcomes |
|---|---|---|---|---|
| NCT02366728 | II | 100 | CMV pp65 DC vaccine +111In-labeled DC vaccine + Td Toxoid + basiliximab | OS |
| NCT02465268 | II | 175 | pp65-shLAMP DC dendritic cell vaccine with GM-CSF | OS |
| NCT02924038 | I | 30 | IMA-950 (peptide vaccine comprising multiple GAAs) and poly-ICLC ± varlilumab (immunostimulatory antiCD27 antibody) | Safety and T-cell responses |
| NCT02960230 | I | 29 | H3.3K27 M peptide vaccine plus Td and poly-ICLC | Safety and OS |
| NCT03018288 | II | 108 | pembrolizumab ± HSPPC-96 vaccine | 1-year OS |
| NCT03400917 | II | 55 | AV-GBM-1 (autologous dendritic cells loaded with tumor associated antigens from a short-term cell culture of autologous tumor cells) | OS |
| NCT04116658 | II | 52 | EO2401 peptide vaccine | Safety and tolerability |
Abbreviations: GBM = glioblastoma multiforme, OS = overall survival.